Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Valneva SE Pref.

Market Cap 437M 501M 405M 379M 711M 47.31B 715M 4.8B 1.86B 23.29B 1.88B 1.84B 80.85B P/E 2026 *
-6.28x
P/E 2027 * 6.07x
Enterprise Value 565M 648M 523M 490M 919M 61.16B 925M 6.21B 2.41B 30.1B 2.43B 2.38B 105B EV / Sales 2026 *
3.72x
EV / Sales 2027 * 1.69x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 501M
+1.44%+1.71%-10.63%-9.16% 43.13B
+3.31%+5.93%+308.19%+562.02% 34.65B
+2.84%+2.14%+6.87%+34.93% 30.03B
-1.70%-7.54%+8.51%-22.34% 28B
-1.90%-1.56%+11.62%+19.80% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+52.04%+107.47% 13.14B
-0.57%-2.43%+5.18%+4.20% 12.53B
-0.26%+1.15%+100.27%+80.69% 12.25B
Average +0.37%+0.73%+60.26%+97.20% 23.61B
Weighted average by Cap. +0.77%+1.27%+65.22%+113.23%

Financials

2026 *2027 *
Net sales 152M 174M 141M 132M 247M 16.43B 248M 1.67B 646M 8.09B 654M 640M 28.08B 294M 337M 272M 255M 478M 31.82B 481M 3.23B 1.25B 15.66B 1.27B 1.24B 54.39B
Net income -66.01M -75.71M -61.14M -57.23M -107M -7.14B -108M -725M -281M -3.52B -284M -278M -12.21B 70.5M 80.86M 65.3M 61.12M 115M 7.63B 115M 775M 300M 3.76B 304M 297M 13.04B
Net Debt 128M 147M 119M 111M 208M 13.85B 209M 1.41B 545M 6.82B 551M 539M 23.68B 60.02M 68.84M 55.59M 52.04M 97.59M 6.5B 98.18M 659M 256M 3.2B 258M 253M 11.1B
Logo Valneva SE Pref.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.305EUR
Average target price
5.233EUR
Spread / Average Target
+127.04%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!